Samsung Biologics building in Incheon / Korea Times photo by Shim Hyun-chul
Samsung Life Science Fund announced Thursday it will invest in Cartography Biosciences, a U.S. biotech company focused on tumor-specific antigen discovery.
Samsung Life Science Fund is a venture investment fund jointly capitalized by Samsung C&T, Samsung Biologics and Samsung Bioepis, and managed by Samsung Venture Investment. The fund focuses on identifying global companies with innovative biotechnology to secure future growth engines.
Cartography Biosciences holds a proprietary platform technology that combines single-cell genomic data with advanced bioinformatics to identify antigens. Through its in-house ATLAS and SUMMIT platforms, the company identifies tumor-specific antigens and antigen combinations, enabling the design of antibody therapies with greater targeting precision. Its lead pipeline candidate, CBI-1214, is a T-cell engager targeting colorectal cancer that entered Phase 1 clinical trials in early 2026 and is currently enrolling patients.
Samsung said it plans to use the investment to expand a foundation for global collaboration with Cartography Biosciences, leveraging the U.S. firm's capabilities in genomic data-based antigen discovery and drug development to support promising technologies in the next-generation oncology space.
"Cartography is a next-generation biotech innovator that combines single-cell genomic data by cancer type with bioinformatics in a way that can transform the treatment paradigm," said Hyeongnam Jeong, executive vice president and head of the Bio R&D Center at Samsung Biologics. "We will continue to support innovative technologies that bring meaningful change to patients around the world."
Kevin Parker, co-founder and CEO of Cartography Biosciences, said Samsung is "the ideal partner" aligned with the company's goal of developing differentiated therapies through precise analysis of tumor biology.
"We are delighted to be working with a global leader that recognizes the value of new technologies and cutting-edge biological engineering," he said.
This article was published with the assistance of generative AI and edited by The Korea Times.
Source: Korea Times News
